Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Description

Listen to a new Journal Club with PI Dr. Brian Slomovitz and moderator Dr. Leslie Randall as they discuss details on the New England Journal of Medicine published article Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

Click here to read The New England Journal of Medicine article

Click here to listen to podcast

Presented by:

Brian Slomovitz
Director of Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinani Medical Center
USA

Moderated by:

Leslie Randall
Director of Gynecologic Oncology Clinical Research and Gynecologic Cancer Service Line
Inova Schar Cancer Institute
Inova Health System
USA

Supported in part by

Summary


Availability:	On-Demand


Cost:	FREE

Create Account

Recommended

An Evolving Frontier: Endometrial Cancer Treatment

FREE

Phase II PICCOLO Trial Results

Results of Phase II PICCOLO Trial are available. Dr. Angeles Alvarez Secord, PI of PICCOLO Trial, and Dr. Wendel Naumann discuss results of MIRV in Recurrent Platinum-Sensitive Ovarian Cancer with High Folate Receptor-Alpha Expression.

FREE

Journal Club: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

FREE

IGCS 2024 Cervical Master Sessions: Moving Fowards

FREE

International Gynecologic Cancer Society and International Journal of Gynecological Cancer Evidence-Based Medicine for Gynecological Oncology Curriculum (EBM on the GO)

FREE

Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer

FREE

Multidisciplinary Approach to Treating Advanced Endometrial Cancer

FREE

Preinvasive Disease Program

Preinvasive Disease Program is an IGCS member benefit.

FREE

Moving Towards Personalized Therapy in Endometrial Cancer

FREE